CALR mutation burden in essential thrombocythemia and disease outcome

2.

Klampfl

T

,

Gisslinger

H

,

Harutyunyan

AS

, et al.

Somatic mutations of calreticulin in myeloproliferative neoplasms

.

N Engl J Med

.

2013

;

369

(

25

):

2379

-

2390

.

3.

Guglielmelli

P

,

Maccari

C

,

Sordi

B

, et al.

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

.

Blood Cancer J

.

2023

;

13

(

1

):

21

.

4.

Stengel

A

,

Jeromin

S

,

Haferlach

T

,

Meggendorfer

M

,

Kern

W

,

Haferlach

C

.

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease

.

Haematologica

.

2019

;

104

(

5

):

e187

-

e190

.

5.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

6.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

7.

Thiele

J

,

Kvasnicka

HM

,

Orazi

A

, et al.

The International Consensus Classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms

.

Am J Hematol

.

2023

;

98

(

3

):

544

-

545

.

8.

Barosi

G

,

Mesa

RA

,

Thiele

J

, et al.

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for myelofibrosis research and treatment

.

Leukemia

.

2008

;

22

(

2

):

437

-

438

.

9.

Guglielmelli

P

,

Lasho

TL

,

Rotunno

G

, et al.

MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis

.

J Clin Oncol

.

2018

;

36

(

4

):

310

-

318

.

10.

Tefferi

A

,

Wassie

EA

,

Guglielmelli

P

, et al.

Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

.

Am J Hematol

.

2014

;

89

(

8

):

e121

-

124

.

11.

Rumi

E

,

Pietra

D

,

Ferretti

V

, et al.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

.

Blood

.

2014

;

123

(

10

):

1544

-

1551

.

12.

Rotunno

G

,

Mannarelli

C

,

Guglielmelli

P

, et al.

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

.

Blood

.

2014

;

123

(

10

):

1552

-

1555

.

13.

Barbui

T

,

Vannucchi

AM

,

Buxhofer-Ausch

V

, et al.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

.

Blood Cancer J

.

2015

;

5

(

11

):

e369

.

14.

Passamonti

F

,

Thiele

J

,

Girodon

F

, et al.

A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT

.

Blood

.

2012

;

120

(

6

):

1197

-

1201

.

15.

Loscocco

GG

,

Guglielmelli

P

,

Gangat

N

, et al.

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients

.

Am J Hematol

.

2021

;

96

(

11

):

1472

-

1480

.

16.

Vannucchi

AM

,

Antonioli

E

,

Guglielmelli

P

, et al.

Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia

.

Blood

.

2007

;

110

(

3

):

840

-

846

.

17.

Passamonti

F

,

Rumi

E

,

Pietra

D

, et al.

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

.

Leukemia

.

2010

;

24

(

9

):

1574

-

1579

.

18.

Bertozzi

I

,

Biagetti

G

,

Vezzaro

T

, et al.

Clinical effect of CALR allele burden in patients with essential thrombocythemia

.

Ann Hematol

.

2022

;

101

(

6

):

1345

-

1346

.

19.

Barbui

T

,

Thiele

J

,

Passamonti

F

, et al.

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome

.

Blood

.

2012

;

119

(

10

):

2239

-

2241

.

20.

Reis

E

,

Buonpane

R

,

Celik

H

, et al.

Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs)

.

Blood

.

2022

;

140

(

suppl 1

):

14

-

15

.